Eli Lilly and Company (NYSE:LLY) Given New $1,230.00 Price Target at Cantor Fitzgerald

Eli Lilly and Company (NYSE:LLY) had its price target increased by stock analysts at Cantor Fitzgerald from $1,205.00 to $1,230.00 in a research note issued on Friday, Marketbeat.com reports. The brokerage presently has an “overweight” rating on the stock. Cantor Fitzgerald’s target price indicates a potential upside of 26.32% from the stock’s current price.

Several other analysts have also recently commented on LLY. Wells Fargo & Company raised their price target on shares of Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. Leerink Partners decreased their price target on shares of Eli Lilly and Company from $1,296.00 to $1,058.00 and set an “outperform” rating for the company in a report on Monday. UBS Group restated a “buy” rating on shares of Eli Lilly and Company in a report on Wednesday, March 18th. Weiss Ratings restated a “buy (b)” rating on shares of Eli Lilly and Company in a report on Friday, March 27th. Finally, Guggenheim raised their price target on shares of Eli Lilly and Company from $1,163.00 to $1,183.00 and gave the stock a “buy” rating in a report on Tuesday, April 21st. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average target price of $1,218.30.

Eli Lilly and Company Stock Up 4.2%

Shares of LLY stock traded up $39.12 during trading on Friday, hitting $973.72. 709,524 shares of the company were exchanged, compared to its average volume of 3,150,024. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. The firm has a market capitalization of $919.99 billion, a price-to-earnings ratio of 42.62, a P/E/G ratio of 1.00 and a beta of 0.51. The business’s 50-day simple moving average is $947.05 and its 200 day simple moving average is $984.98. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The firm’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same period last year, the company posted $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, analysts forecast that Eli Lilly and Company will post 33.79 EPS for the current fiscal year.

Institutional Trading of Eli Lilly and Company

A number of institutional investors have recently added to or reduced their stakes in LLY. Brighton Jones LLC lifted its stake in Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after acquiring an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC lifted its stake in shares of Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after buying an additional 40 shares during the last quarter. Schnieders Capital Management LLC. lifted its stake in shares of Eli Lilly and Company by 16.7% in the second quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock worth $6,231,000 after buying an additional 1,141 shares during the last quarter. Flow Traders U.S. LLC acquired a new stake in shares of Eli Lilly and Company in the second quarter worth $356,000. Finally, Nebula Research & Development LLC acquired a new stake in shares of Eli Lilly and Company in the second quarter worth $749,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly crushed Q1 estimates and raised full‑year guidance — strong GLP‑1 volume drove 56% revenue growth and management boosted FY26 revenue and EPS targets, a primary catalyst for the stock lift. Eli Lilly crushes Q1 estimates, raises full-year outlook
• Positive Sentiment: Foundayo oral GLP‑1 pill is already reaching patients (CEO: >20,000 prescriptions early), supporting upside to the obesity pill opportunity and long‑term GLP‑1 adoption. Lilly’s weight loss pill reaches brand new patients
• Positive Sentiment: FDA proposed excluding active ingredients for tirzepatide/semaglutide from bulk compounding — could limit cheaper compounded competitors and protect branded volumes/pricing. US FDA proposes excluding weight-loss drugs from compounding list
• Positive Sentiment: Market commentary and upgrades: analysts and investors upgraded/touted LLY after the print (Seeking Alpha upgrade, Guggenheim PT raise), reinforcing buy-side interest. Eli Lilly: Buying Opportunity (Rating Upgrade)
• Neutral Sentiment: Corporate activity supports pipeline expansion — acquisition of Ajax (JAK inhibitors) and a $2.25B AI/gene‑editing partnership broaden long‑term growth drivers but are multi‑year value creators. Why Eli Lilly is One of the Best Drug Stocks
• Neutral Sentiment: Summaries/transcripts of the earnings call and analyst notes provide color (Moby, Seeking Alpha transcript) for investors assessing sustainability of volume vs. pricing trends. Eli Lilly Q1 2026 Earnings Call Summary
• Negative Sentiment: Competition and mixed early pill metrics: social/industry notes point to a slower Foundayo launch vs. competitors in week‑to‑week scripts, and Novo remains a strong rival — this could cap near‑term share gains. Opinions on Foundayo Pill Launch
• Negative Sentiment: Valuation and selling activity: coverage notes call LLY an expensive stock even as some investors and insiders have been selling; high multiples raise sensitivity to any slowdown in GLP‑1 momentum. Valuation commentary from Gary Black

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.